Abstract
Dimethyl sulfoxide (DMSO) is an FDA-approved organosulfur solvent that is reported to have therapeutic value in osteoarthritis and osteopenia. DMSO is used as a cryoprotectant for the cryopreservation of bone grafts and mesenchymal stem cells which are later used for bone repair. It is also used as a solvent in the preparation of various scaffolds used for bone tissue engineering purposes. DMSO has been reported to inhibit osteoclast formation in vitro but the mechanism involved has remained elusive. We investigated the effect of DMSO on osteoclast differentiation and function using a conventional model system of RAW 264.7 cells. The differentiation of RAW 264.7 cells was induced by adding 50 ng/ml RANKL and the effect of DMSO (0.01 and 1 % v/v) on RANKL-induced osteoclastogenesis was investigated. Addition of 1 % DMSO significantly inhibited RANKL-induced formation of TRAP+, multinucleated, mature osteoclasts and osteoclast late-stage precursors (c-Kit− c-Fms+ Mac-1+ RANK+). While DMSO did not inhibit proliferation per se, it did inhibit the effect of RANKL on proliferation of RAW 264.7 cells. Key genes related to osteoclast function (TRAP, Integrin αVβ3, Cathepsin K and MMP9) were significantly down-regulated by DMSO. RANKL-induced expression of RANK gene was significantly reduced in the presence of DMSO. Our data, and reports from other investigators, that DMSO enhances osteoblastic differentiation of mesenchymal stem cells and also prevents bone loss in ovarietcomized rats, suggest that DMSO has tremendous potential in the treatment of osteoporosis and bone diseases arising from uncontrolled activities of the osteoclasts.
Similar content being viewed by others
References
Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM, Suda T (1999) Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 190:1741–1754
Berz D, McCormack EM, Winer ES, Colvin GA, Quesenberry PJ (2007) Cryopreservation of hematopoietic stem cells. Am J Hematol 82:463–472
Brien S, Prescott P, Bashir N, Lewith H, Lewith G (2008) Systematic review of the nutritional supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) in the treatment of osteoarthritis. Osteoarthr Cartil 16:1277–1288
Brien S, Prescott P, Lewith G (2011) Meta-analysis of the related nutritional supplements dimethyl sulfoxide and methylsulfonylmethane in the treatment of osteoarthritis of the knee. Evid Based Complement Alternat Med 2011:528403
Capriotti K, Capriotti JA (2012) Dimethyl sulfoxide: history, chemistry, and clinical utility in dermatology. J Clin Aesthet Dermatol 5:24–26
Cheung WM, Ng WW, Kung AW (2006) Dimethyl sulfoxide as an inducer of differentiation in preosteoblast MC3T3-E1 cells. FEBS Lett 580:121–126
Demos CH, Beckloff GL, Donin MN, Oliver PM (1967) DMSO in musculoskeletal disorders. Ann NY Acad Sci 141:517–523
Egli RJ, Sckell A, Fraitzl CR, Felix R, Ganz R, Hofstetter W, Leunig M (2003) Cryopreservation with dimethyl sulfoxide sustains partially the biological function of osteochondral tissue. Bone 33:352–361
Fuller P, Roth S (2011) Diclofenac sodium topical solution with dimethyl sulfoxide, a viable alternative to oral nonsteroidal anti-inflammatories in osteoarthritis: review of current evidence. J Multidiscip Healthc 4:223–231
Ha H, Kwak HB, Lee SW, Jin HM, Kim HM, Kim HH, Lee ZH (2004) Reactive oxygen species mediate RANK signaling in osteoclasts. Exp Cell Res 301:119–127
He X, Andersson G, Lindgren U, Li Y (2010) Resveratrol prevents RANKL-induced osteoclast differentiation of murine osteoclast progenitor RAW 264.7 cells through inhibition of ROS production. Biochem Biophys Res Commun 401:356–362
John H, Laudahn G (1967) Clinical experiences with topical application of DMSO in orthopedic diseases. Evaluation of 4180 cases. Ann NY Acad Sci 141:506–516
Kofron MD, Opsitnick NC, Attawia MA, Laurencin CT (2003) Cryopreservation of tissue engineered constructs for bone. J Orthop Res 21:1005–1010
Lee NK, Choi YG, Baik JY, Han SY, Jeong DW, Bae YS, Kim N, Lee SY (2005) A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood 106:852–859
Lemieux JM, Wu G, Morgan JA, Kacena MA (2011) DMSO regulates osteoclast development in vitro. In Vitro Cell Dev Biol Anim 47:260–267
Liu H, Yang X, Zhang Y, Dighe A, Li X, Cui Q (2012) Fullerol antagonizes dexamethasone-induced oxidative stress and adipogenesis while enhancing osteogenesis in a cloned bone marrow mesenchymal stem cell. J Orthop Res 30:1051–1057
Lockie ML, Norcross BM (1967) A clinical study on the effects of DMSO in 103 patients with acute and chronic musculoskeletal injuries and inflammations. Ann NY Acad Sci 141:599–602
Matsumoto J (1967) Clinical trials of dimethyl sulfoxide in rheumatoid arthritis patients in Japan. Ann NY Acad Sci 141:560–568
Moon HJ, Kim SE, Yun YP, Hwang YS, Bang JB, Park JH, Kwon IK (2011) Simvastatin inhibits osteoclast differentiation by scavenging reactive oxygen species. Exp Mol Med 43:605–612
Moon HJ, Ko WK, Han SW, Kim DS, Hwang YS, Park HK, Kwon IK (2012) Antioxidants, like coenzyme Q10, selenite, and curcumin, inhibited osteoclast differentiation by suppressing reactive oxygen species generation. Biochem Biophys Res Commun 418:247–253
Morelli V, Naquin C, Weaver V (2003) Alternative therapies for traditional disease states: osteoarthritis. Am Fam Physician 67:339–344
Parent M, Nouvel C, Koerber M, Sapin A, Maincent P, Boudier A (2013) PLGA in situ implants formed by phase inversion: Critical physicochemical parameters to modulate drug release. J Control Release 172:292–304
Paul MM (1967) Interval therapy with DMSO. Ann NY Acad Sci 141:586–598
Rosenbaum EE, Herschler RJ, Jacob SW (1965) DMSO in musculoskeletal disorders. JAMA 192:309–313
Santos NC, Figueira-Coelho J, Martins-Silva J, Saldanha C (2003) Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects. Biochem Pharmacol 65:1035–1041
Shu Z, Heimfeld S, Gao D (2013) Hematopoietic SCT with cryopreserved grafts: adverse reactions after transplantation and cryoprotectant removal before infusion. Bone Marrow Transplant [Epub ahead of print]
Steinberg A (1967) The employment of dimethyl sulfoxide as an antiinflammatory agent and steroid-transporter in diversified clinical diseases. Ann NY Acad Sci 141:532–550
Stephens AS, Stephens SR, Hobbs C, Hutmacher DW, Bacic-Welsh D, Woodruff MA, Morrison NA (2011) Myocyte enhancer factor 2c, an osteoblast transcription factor identified by dimethyl sulfoxide (DMSO)-enhanced mineralization. J Biol Chem 286:30071–30086
Takayanagi H (2007) Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7:292–304
Tamjidipoor A, Tavafi M, Ahmadvand H (2013) Effect of dimethyl sulfoxide on inhibition of post-ovariectomy osteopenia in rats. Connect Tissue Res 54:426–431
Trice JM, Pinals RS (1985) Dimethyl sulfoxide: a review of its use in the rheumatic disorders. Semin Arthritis Rheum 15:45–60
Väänänen HK, Zhao H, Mulari M, Halleen JM (2000) The cell biology of osteoclast function. J Cell Sci 113:377–381
Yang X, Ebrahimi A, Li J, Cui Q (2014) Fullerene-biomolecule conjugates and their biomedicinal applications. Int J Nanomedicine 9:77–92
Acknowledgments
This work was supported by grants from the Orthopaedic Research and Education Foundation (OREF), the Musculoskeletal Transplant Foundation (MTF) and the Orthopaedic Trauma Association (OTA) to QC. CY was supported by a grant from the National Natural Science Foundation of China (81101344/HO604) during the course of this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yang, C., Madhu, V., Thomas, C. et al. Inhibition of differentiation and function of osteoclasts by dimethyl sulfoxide (DMSO). Cell Tissue Res 362, 577–585 (2015). https://doi.org/10.1007/s00441-015-2245-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00441-015-2245-1